HK$ 90
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E.
Target Price
The average target price of 1801.HK is 102 and suggests 14% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio
